BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
Abstract KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRASG12C inhibitors is limited by intrinsi...
Збережено в:
| Автори: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2022-03-01
|
| Серія: | Journal of Hematology & Oncology |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s13045-022-01241-3 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|